PercuVision Expands Board of Directors, As Company Focuses On Growth
Summary
COLUMBUS, Ohio, Jan. 5, 2016 /PRNewswire/ -- PercuVision® LLC, developer of patented micro-endoscope technologies to reduce pain and morbidity from blind urinary catheterizations, today announced that Thomas McDonald and Geoffrey Madden have been appointed to the companys board of directors. PercuVision currently is marketing its FDA-cleared DirectVision® System, a medical device that lets health practitioners view in real-time the inside of the urethra when placing urinary catheters. "We will continue to leverage the boards expertise and our companys leadership position, as we market our patented technology to the multi-billion dollar catheterization market, and as we further develop our technology for other applications, including nasogastric intubation, all with an objective of helping to improve patient care and outcomes," Dr. Singh added. McDonald currently is chairman of the board of trustees of the MetroHealth Medical Center, an affiliate of the Case Western Reserve University School of Medicine, as well as a member of the board of the directors of Diasome Pharmaceuticals, Inc., a biotech company focused on the clinical and commercial development of breakthrough therapies for diabetes. About PercuVision PercuVision® LLCs mission is to improve patient care and safety by applying micro fiber-optic bundle technology to common global medical procedures.